Specific Biologics raises $35 million for ALS gene editing
Specific Biologics raised $35 million to move a C9ORF72-linked ALS gene-editing candidate into an adaptive Phase I/II trial, backed by an expanded investor syndicate.
Topic
Als
Topic
Topic
Topic
Specific Biologics raised $35 million to move a C9ORF72-linked ALS gene-editing candidate into an adaptive Phase I/II trial, backed by an expanded investor syndicate.